Palantir's Commercial Surge Draws a Fresh Bull Call as Insiders Head for the Exit
Published on 11/11/2026 at 15:01 | Editorial boerse-global.de
Fubon initiated coverage of Palantir with a buy rating and a $200 price target, a day after the data-analytics company's stock moved up 1.9% in premarket trading to €154.30. The call lands as Wall Street remains visibly split on how much of Palantir's blistering growth is already baked into the share price.
RBC Capital took the opposite tack on November 3, lifting its target to $130 from $90 while analyst Rishi Jaluria kept an "Underperform" rating — a signal that he expects the stock to lag the broader market. The gap between the two houses is wide, and it mirrors a broader debate over a company whose revenue is expanding at a pace few large software firms have matched.
That expansion is the core of the bull case. Palantir posted third-quarter 2026 revenue of $2.313 billion, up 96% year over year, and recently raised its full-year 2026 revenue guidance to a range of $8.530 billion to $8.534 billion. The shares, however, slipped following the quarterly report — a reminder that expectations for the company have climbed just as steeply as its top line.
The US commercial engine takes the lead
What stands out inside the numbers is where the growth is coming from. US commercial revenue jumped 148% to $984 million, overtaking the $953 million brought in from US government customers. That shift matters: it suggests Palantir's expansion is increasingly being driven by businesses embedding its platforms in their own operations, rather than by federal contracts alone.
Should investors sell immediately? Or is it worth buying Palantir?
The company's ability to keep converting that demand into signed work will determine whether the optimism holds. New partnerships are the clearest test of that, particularly when they show how customers intend to use Palantir's tools day to day.
Insurance and footwear widen the footprint
AmeriLife Group announced a company-wide partnership with Palantir on November 5, deploying Foundry and the Artificial Intelligence Platform across sales operations in its Health and Wealth divisions. Crump Life Insurance Services is leading the rollout, where applications were already running in production and the broader deployment had begun. No contract value was disclosed, so the economic weight of the deal will hinge on execution.
Changshin signed its own partnership the same day, aimed at linking shoe development, planning and factory production through data and artificial intelligence. Together the two deals sketch out how far Palantir's commercial ambitions now reach — from life insurance distribution to the factory floor.
Palantir at a turning point? This analysis reveals what investors need to know now.
Insider selling in the mix
Against that operational backdrop, a planned share sale by Shyam Sankar has drawn attention, though the size of the intended sale is what makes the filing notable. Such pre-arranged sales carry limited signal on their own; they tend to matter more when the business picture is deteriorating at the same time. For now, the recent figures point the other way, toward strong expansion.
The takeaway is a company whose commercial momentum is doing the heavy lifting in the investment case, with insider sales and a divided analyst community as background noise. That view comes with a condition attached: Palantir has to keep backing up its rapid growth with further successful deployments of its platforms. The AmeriLife rollout, the Changshin tie-up and the pace of US commercial revenue are where that confidence will be measured.
Ad
Palantir Stock: New Analysis - 11 November
Fresh Palantir information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
